| 摘要 |
A pharmaceutical preparation contains a combination of a specific cyclic pentapeptide (I) with a chemotherapeutic agent (II) and/or an angiogenesis inhibitor (III). A pharmaceutical preparation contains (a) the cyclic pentapeptide of formula cyclo-(Arg-Gly-Asp-D-Phe-NMe-Val) (I) and/or its salt with (b) one or more of chemotherapeutic agents (II), angiogenesis inhibitors (III) and their salts. Independent claims are included for: (i) the use of (I) and (II) and/or (III) (all optionally as salts), successively or in physical combination, for the preparation of a medicament for tumor treatment; (ii) the use of (I) and (II) (both optionally as salts), successively or in physical combination, for tumor treatment; and (iii) a kit comprising separately packaged (I) and (II). ACTIVITY : Cytostatic; antithrombotic; cardiovascular; antiarteriosclerotic; osteopathic; antiinflammatory; ophthalmological; antiarthritic; antirheumatic; gastrointestinal; antipsoriatic; antibacterial; antiviral; antifungal; renal. A protocol for testing antitumor activity against transplanted Lewis lung carcinoma in mice is described, but no results are given. MECHANISM OF ACTION : Integrin inhibitor. |
